Related references
Note: Only part of the references are listed.Rituximab in AChR subtype of myasthenia gravis: systematic review
Vincenzo Di Stefano et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2020)
Low-dose rituximab every 6 months for the treatment of acetylcholine receptor-positive refractory generalized myasthenia gravis
Jun Lu et al.
MUSCLE & NERVE (2020)
Estrogen Receptor, Inflammatory, and FOXO Transcription Factors Regulate Expression of Myasthenia Gravis-Associated Circulating microRNAs
Alyson A. Fiorillo et al.
FRONTIERS IN IMMUNOLOGY (2020)
Long-Lasting Rituximab-Induced Reduction of Specific-But Not Total-IgG4 in MuSK-Positive Myasthenia Gravis
Mariapaola Marino et al.
FRONTIERS IN IMMUNOLOGY (2020)
Repeated low-dose rituximab treatment based on the assessment of circulating B cells in patients with refractory myasthenia gravis
Kyomin Choi et al.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2019)
Role of exosomal competing endogenous RNA in patients with hepatocellular carcinoma
Asmaa Abd El Gwad et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2018)
MicroRNA in vivo precipitation identifies miR-151-3p as a computational unpredictable miRNA to target Stat3 and inhibits innate IL-6 production
Xiang Liu et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2018)
Association of a TNFSF13B (BAFF) regulatory region single nucleotide polymorphism with response to rituximab in antineutrophil cytoplasmic antibody-associated vasculitis
Federico Alberici et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2017)
Responsiveness to low-dose rituximab in refractory generalized myasthenia gravis
Sisi Jing et al.
JOURNAL OF NEUROIMMUNOLOGY (2017)
Rituximab as treatment for anti-MuSK myasthenia gravis Multicenter blinded prospective review
Michael K. Hehir et al.
NEUROLOGY (2017)
Durability of the Rituximab Response in Acetylcholine Receptor Autoantibody-Positive Myasthenia Gravis
Kimberly R. Robeson et al.
JAMA NEUROLOGY (2017)
Autoantibody-producing plasmablasts after B cell depletion identified in muscle-specific kinase myasthenia gravis
Panos Stathopoulos et al.
JCI INSIGHT (2017)
A pipeline to quantify serum and cerebrospinal fluid microRNAs for diagnosis and detection of relapse in paediatric malignant germ-cell tumours
Matthew J. Murray et al.
BRITISH JOURNAL OF CANCER (2016)
Disease specific enrichment of circulating let-7 family microRNA in MuSK plus myasthenia gravis
Tanel Punga et al.
JOURNAL OF NEUROIMMUNOLOGY (2016)
The expanding field of IgG4-mediated neurological autoimmune disorders
M. G. Huijbers et al.
EUROPEAN JOURNAL OF NEUROLOGY (2015)
Myasthenia gravis: subgroup classification and therapeutic strategies
Nils Erik Gilhus et al.
LANCET NEUROLOGY (2015)
Association between-871C>T promoter polymorphism in the B-cell activating factor gene and the response to rituximab in rheumatoid arthritis patients
Adeline Ruyssen-Witrand et al.
RHEUMATOLOGY (2013)
Management challenges in muscle-specific tyrosine kinase myasthenia gravis
Amelia Evoli et al.
MYASTHENIA GRAVIS AND RELATED DISORDERS I (2012)
Long-lasting treatment effect of rituximab in MuSK myasthenia
J. Diaz-Manera et al.
NEUROLOGY (2012)
Use and monitoring of low dose rituximab in myasthenia gravis
Stefan Blum et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2011)
THE MG-QOL15 FOR FOLLOWING THE HEALTH-RELATED QUALITY OF LIFE OF PATIENTS WITH MYASTHENIA GRAVIS
Ted M. Burns et al.
MUSCLE & NERVE (2011)
Characterization of extracellular circulating microRNA
Andrey Turchinovich et al.
NUCLEIC ACIDS RESEARCH (2011)
The MG Composite A valid and reliable outcome measure for myasthenia gravis
Ted M. Burns et al.
NEUROLOGY (2010)
Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases
Xi Chen et al.
CELL RESEARCH (2008)
Sustained response to Rituximab in anti-AChR and anti-MuSK positive Myasthenia Gravis patients
Isabel Illa et al.
JOURNAL OF NEUROIMMUNOLOGY (2008)
Circulating microRNAs as stable blood-based markers for cancer detection
Patrick S. Mitchell et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjogren's syndrome
Jacques-Olivier Pers et al.
ARTHRITIS AND RHEUMATISM (2007)
Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production
Frederic Lavie et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
Muscle-specific receptor tyrosine kinase autoantibodies - a new immunoprecipitation assay
I Matthews et al.
CLINICA CHIMICA ACTA (2004)
Share Paper
